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Abstract 
 Cancer treatments often reach a refractory period leading to treatment failure and 
patients developing disease recurrence. This can be due to tumour cells escaping the immune 
response and creating an immunosuppressive microenvironment enhancing cancer 
progression. Immunotherapy has become a promising tool for cancer treatment as it restores 
the anti-tumour response of the patient’s immune system. Immune checkpoint inhibitors are 
the most widely studied immunotherapies worldwide and are now approved for multiple 
cancers. However, CAR-T cell therapy has also shown promise by targeting T-lymphocytes 
that are genetically modified ex vivo to expressed chimeric antigen receptors and this is now 
approved to treat some haematological cancers. Although immunotherapy has shown 
successful treatment outcomes in multiple cancers, some patients do not respond to this 
treatment. Therefore, approaches to enhance the efficacy of immunotherapies are likely to be 
the key to improving their effectiveness. Therefore, combination therapies of checkpoint 
inhibitors +/- chemotherapy are at the forefront of current research. Furthermore, biomarkers 
that predict treatment response are now beginning to emerge. Additionally, utilizing 
nanoparticles as a new-targeted drug delivery system to enhance CAR-T cell therapy may 
enhance the efficacy of the cells when re-infused within the patient. Even if efficacy is 
enhanced, severe immune-related adverse events (irAEs) occur that are life threatening and 
could lead to therapy being stopped. Therefore, predictive biomarkers for toxicity are also 
needed to improve both the patient’s quality of life and treatment outcomes. This review will 
look at the current immunotherapies in clinical trials and discuss how to enhance their 
efficacy. 
 
Keywords- immunotherapy, immune checkpoint inhibitor, biomarker, adoptive cell therapy, 
colorectal cancer  
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1. Introduction 
Cancer therapy is mainly focussed on surgery, chemotherapy, radiotherapy, and 
endocrine therapy (1). However, these strategies frequently reach a refractory period leading 
to treatment failure and the patient developing disease recurrence (2, 3). One solution may be 
to focus on enhancing the patient’s own immune system to attack the tumour; as once cancer 
is initiated, it can progress as a result of tumour cells escaping from the immune system. 
Tumour cells can escape the immune response in variety ways in order to survive and further 
progress without being attacked by immune cells (4). Additionally, tumour cells can prevent 
immune cell actions, with the support of multiple cell types to create an immunosuppressive 
microenvironment (5). Therefore, tumour escape from immunologic control is confirmed as 
one of the hallmarks of cancer (6).  
The immune responses recognise tumour cells and eradicate them by multiple 
processes involving cooperation of both the innate and adaptive arms (7, 8). This process 
involves both positive and negative regulators. Positive regulators enhance anti-tumour 
activity, whereas negative regulators inhibit this killing process and enhance tumour growth 
instead. Therefore, immunotherapy that targets the negative regulators to enhance the anti-
tumour responses could be a promising alternative treatment strategy and may be a powerful 
tool to treat cancer.  
Immunotherapy is now a main focus for many cancer types; it works by restoring the 
patient’s immune responses to eliminate tumour cells  (9, 10). It can be classified as active or 
passive by assessing the mechanism by which the therapy activates an immune response (11). 
Active immunotherapy includes preventive and therapeutic vaccines, immunomodulatory 
monoclonal antibodies, i.e. immune checkpoint inhibitors, and immunostimulatory cytokines, 
that stimulate the host’s adaptive immune response in situ. Passive immunotherapy focuses 
on activating the host’s immune response in vitro and transfers it back to the host known as 
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adoptive cell transfer or cell-based therapy, i.e. chimeric antigen receptor CAR-T cell 
therapy.  
This review summarizes two types of immunotherapy; immune checkpoint inhibitors, 
and adoptive T-cell transfer in detail within the cancer setting.  Immune checkpoint inhibitors 
focuses on anti PD-1/anti PD-L1/anti CTLA-4; as the mechanism of immune checkpoint 
proteins on T-cells (PD-1, PD-L1, CTLA-4) is to bind to their receptors on tumour cells or 
antigen presenting cells, which causes a negative effect by inhibiting T-cells function. 
Therefore, blocking the binding of immune checkpoint protein and their receptors could 
restore T-cells function to kill tumour cells. Whereas adoptive T-cell transfer or CAR T-cells; 
utilise T-cells from patients that are engineered in vitro to express chimeric antigen receptors 
which induces binding to tumour cell antigens and enhance T-cells function, which causes a 
positive effect to kill tumour cells.  The review will also discuss strategies to enhance 
immunotherapy efficacy and how they relate to the effectiveness of treatment outcomes. 
 
2. Immune checkpoints and their inhibitors 
Active immunotherapy targets the host’s immune response to induce activation and 
restore anti-tumour function, one example of this are checkpoint inhibitors. Immune 
checkpoints are negative regulators of the immune system and play a crucial role in limiting 
anti-tumour immune responses. In the normal anti-cancer immune response; antigens on the 
surface of tumour cells bind to checkpoint proteins on the surface of T-lymphocytes leading 
to decreased T-cell function. This controls the anti-tumour response and avoids T-cell 
exhaustion; however, the tumour can hijack this mechanism to suppress anti-tumour 
functions and promotes tumour progression. Therefore, these immune checkpoints are 
important immunotherapeutic targets, with checkpoint blockade inhibiting this immune 
system modulation resulting in increased effector T-cells that can coordinate an anti-tumour 
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response (12). Immune checkpoint inhibitors are the most widely studied active 
immunotherapy in cancer research leading to some having been approved for clinical use 
(13). Two types of co-inhibitory proteins that are widely studied are programmed cell death 
protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) (Figure 1). 
2.1 PD-1 and PD-L1  
PD-1, known as CD279, is a type I transmembrane protein, a member of the CD28 
family which is expressed on activated and exhausted T- and B-lymphocyte. PD-1 is 
expressed during the effector phase in peripheral tissue and is upregulated in many tumours. 
It binds to specific ligands, called PD-L1 (the program cell death ligand-1) and PD-L2 (the 
program cell death ligand-2), on tumour cells.  
PD-L1 is expressed on various types of solid tumours, but is not expressed in normal 
epithelial tissue, where, PD-L2 is the dominant form. When PD-1 binds to PD-L1 there is 
decreased cytokine production and inhibition of T-cells proliferation and function within 
peripheral tissues and tumours. This plays a key role in negative immune cell regulation 
resulting in tumour immunity balancing and attenuation of the T-lymphocyte response within 
the tumour microenvironment (14, 15). 
2.2 CTLA-4  
CTLA-4, also known as CD152, is a CD28 homolog membrane glycoprotein on T-
lymphocyte, found during the priming phase in lymph nodes. CTLA-4 interacts with specific 
protein (B7) on antigen presenting cells (APC) to produce co-inhibitory signals to decrease 
T-lymphocyte anti-tumour responses (16). This was the first pathway for immune checkpoint 
regulation that was proposed in 1996 by Leach et al. (17).   
2.3 Immune checkpoints inhibitors to block ligand binding that inhibits T-cell 
functions  
 Immune checkpoint interactions can be blocked with anti-PD-1/anti-PD-L1/anti-
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CTLA-4 antibodies leading to immune cell re-activation and a coordinated anti-tumour 
response of T-cells. Currently, three anti-PD-1 immune checkpoint inhibitors, 
pembrolizumab, nivolumab, and cemiplimab are approved for use within the clinical setting. 
Three anti-PD-L1 antibodies were also approved; atezolizumab, durvalumab, and avelumab. 
Ipilimumab is the only anti-CTLA-4 approved for clinical use (Table 1). 
2.3.1 Anti-PD-1 (Pembrolizumab, Nivolumab, and Cemiplimab)  
Pembrolizumab has been studied in multiple solid tumours and showed anti-tumour 
activity in clinical trials. As a result, in 2014, it was approved to treat advanced melanoma 
based on a phase III studied comparing pembrolizumab and the anti-CTLA-4, ipilimumab; 
pembrolizumab demonstrated prolong overall survival and less toxicity than ipilimumab (18). 
In 2015, pembrolizumab was further approved to treat advanced non-small-cell lung cancer 
(NSCLC) based on the result that it showed anti-tumour activity with manageable side-
effects (19). In 2016, pembrolizumab was approved for recurrent or metastatic head and neck 
squamous cell carcinoma patients (20). A study by Seiwert et al. showed that pembrolizumab 
has efficacy over standard therapy by cetuximab. However, the latest phase III trial by Merck 
and Co., showed that this drug did not result in improved overall survival as previously 
observed (21). This finding did not affect the previous approval but does show variability in 
results for this cancer type and suggests that a predictive biomarker is needed to select 
responsive patients.  
Over the past two years, pembrolizumab has been approved for multiple types of 
cancer including classical Hodgkin lymphoma (cHL), metastatic urothelial carcinoma, gastric 
cancer or gastroesophageal junction (GEJ) adenocarcinoma, and colorectal cancer (CRC). In 
cHL, pembrolizumab was approved based on the study that treated both adults and pediatric 
patients with resistance to current therapy. The result showed a 69% overall response rate 
with 11.1 months of median response duration until reaching unacceptable toxicity (22). In 
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advanced metastatic urothelial carcinoma (mUCC), it was approved based on the phase II 
trial that compared pembrolizumab to chemotherapy. Pembrolizumab showed a median 
overall survival of 10.3 months, whereas chemotherapy only showed a median survival of 7.4 
months (23). In the same year, pembrolizumab was also approved for non-resectable or 
metastatic microsatellite instability-high (MSI-H)/mismatch-repair deficient (dMMR) solid 
tumours including colorectal cancer (20, 24-27). This was the first approval based on the 
specific biomarkers regardless of the origin of tumour. 
In gastric cancer or GEJ adenocarcinoma, pembrolizumab was approved based on the 
phase II KEYNOTE-059 study (28). From the 143 patients, the result showed 13.3% 
objective response rate and response duration of 2.8-19.4 months. MSI-H was observed in 7 
patients showing a 57% objective response rate and response duration from 5.3-14.1 months 
suggesting MSI status could predict response to pembrolizumab as seen in other cancers. 
Recently, pembrolizumab was further approved for treatment of recurrent or metastatic 
cervical cancer for patients who express PD-L1 on tumour cells (29). In the same month, it 
was further approved to treat resistant primary mediating large B-cell lymphoma (PMBCL) 
in adults and pediatrics and showed a 45% response rate (30). However, 26% of patients did 
developed serious adverse effects suggesting further work is still needed in the cancer type. 
 Nivolumab, a second PD-1 inhibitor, has also been investigated in several tumours 
and shown anti-tumour activity. In 2014, it was approved for metastatic melanoma treatment 
(31, 32), and in 2015, nivolumab was further approved for metastatic NSCLC after a study 
demonstrated improved overall survival compered to docetaxel therapy (33). Nivolumab was 
also approved for use in advanced metastatic renal cell carcinoma (RCC) as it showed 
improved overall survival over everolimus (Afinitor) (34). In 2016, nivolumab was approved 
for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after a study 
showed longer overall survival when compared to chemotherapy (35).  
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Recently, in September 2018, cemiplimab (REGN2810) is approved to treat patients 
with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who 
are not candidates for curative surgery or curative radiation (36). There are also many other 
anti-PD-1 antibodies, for example, pidilizumab (a humanized anti-PD-1), AMP-224, 
MEDI0680, PDR001, CT-001, in clinical trials for several tumour types (37). 
2.3.2 Anti-PD-L1 (Atezolizumab, Durvalumab, and Avelumab) 
PD-L1 inhibitors have also been approved for use in solid tumours. Atezolizumab was 
approved for advanced bladder cancer (38) and metastatic NSCLC  in 2016 (39, 40). In 2017, 
avelumab was approved for merkel cell cancer, an aggressive skin cancer, and UCC. In 
merkel cell cancer, avelumab was the first targeted therapy approved for this disease, the 
phase II trial studied avelumab in stage IV chemotherapy refractory disease via an 
international multicenter trial across North America, Europe, Asia, and Australia (41). The 
result showed a 31% response rate and 10.4 months response duration. In UCC, a study in 
mUCC patients showed 11.4 weeks median response rate. However, almost all patients 
developed adverse events (42). Overall, PD-1 and PD-L1 inhibitors have shown good 
response rates across a variety of cancers but further work is needed to enhance their efficacy 
and decrease toxicity. In addition, durvalumab is approved for advanced or mUCC in 2017 
and NSCLC in 2018 (43, 44). 
 2.3.3 Anti-CTLA-4 (Ipilimumab) 
The main CTLA-4 inhibitor studied to date is ipilimumab, a monoclonal antibody that 
was the first checkpoint inhibitor the FDA-approved for advanced melanoma in 2014. It was 
shown to increase T-lymphocyte proliferation and restore the anti-tumour immune response 
(45). Based on the phase III clinical study in unresectable stage III or IV melanoma that 
divided patients into 3 treatment groups, ipilimumab plus glycoprotein 100 (gp100) peptide 
vaccine, ipilimumab alone, and gp100 alone. The result showed that ipilimumab significantly 
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improved patients overall survival compared to the gp100 alone or the combination (46). 
Ipilimumab has now also been approved for use in RCC in combination with nivolumab (47). 
  Tremilimumab, an IgG2 monoclonal antibody, is another anti-CTLA-4 that showed 
satisfactory result in phase I/II studies in advance melanoma (48). However, when test in a 
phase III trial compared with chemotherapy, tremilimumb induced toxicity and showed no 
survival benefit over chemotherapy (49). Therefore, tremilimumab was not approved, but 
further clinical trials are now ongoing to study this drug in combinations with current 
therapies and to assess potential biomarkers to predict treatment response.   
2.3.4 Immune checkpoint inhibitors in colorectal cancer 
Although checkpoint inhibitors have exhibited successful results in other tumours, in 
CRC, the results for immunotherapy are not as favorable. Initial studies showed some 
promising results in metastatic CRC patients with dMMR tumours, but not in MMR 
competent patients, which only represents a small proportion of metastatic patients. 
Therefore, pembrolizumab and nivolumab are only FDA-approved for this small group of 
patients with metastatic dMMR CRC, suggesting that other strategies are required for these 
inhibitors to be translated to a wider range of CRC tumours. 
To address this, immune checkpoint inhibitors are now being trialed in combination 
with chemotherapy, radiotherapy, and other agents that might block factors that suppress the 
immune response or agents that directly stimulate the immune response, to prime for 
immunotherapy use (50). However, there is still a problem with resistance to checkpoint 
inhibitor due to various factors including signaling pathways which inhibit the anti-tumour 
activity of immune cells (51). At the moment, monotherapy or combination therapy to 
enhance the drug efficacy and reduce this resistance rate in CRC is being considered in 
parallel to examining new therapeutic targets.  
Therefore, a combination of pembrolizumab with azacitidine chemotherapy was 
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performed in MMR competent metastatic CRC. The results observed an enhancement of 
pembrolizumab anti-tumour activity when combined with this chemotherapy in these 
patients. The trial is now in phase II with a cohort of 31 MMMR competent metastatic CRC 
patients receiving 200 mg pembrolizumab every 3 weeks and 100 mg azacitidine daily. 
However, the results showed a low response rate (3%) and the median overall survival was 
only 6.2 months. Ten patients did, however, developed rapid stabilization of tumour 
progression but treatment-related adverse events occurred in 63% of patients (52). Therefore, 
pembrolizumab plus azacitidine showed a low anti-tumour activity for MMR competent 
metastatic CRC, however, disease stabilization in some patients may suggest that biomarkers 
are needed to predict those patients that will achieve disease stabilization and those that will 
develop toxicity. Similarly, a combination of nivolumab and ipilimumab was preliminary 
studied and showed potential efficacy in the same cohort. The result from 27 patients showed 
a 41% objective response rate with 78% disease control rate. Tumour-related adverse events 
occurred in 37% of patients but there was no death due to this therapy (53). This study is still 
ongoing to further assess long-term efficacy and analysis of potential predictive biomarkers. 
As the PD-L1 inhibitor, atezolizumab, has shown only a partial response in CRC 
Phase I studies, currently, studies of atezolizumab combined with the vascular endothelial 
growth factor (VEGF) inhibitor bevacizumab, or atezolizumab plus bevacizumab and 
FOLFOX in metastatic CRC are looking promising (54). Both studies showed significant 
anti-tumour effects. Many other anti-PD-L1 compounds are also in ongoing studies for 
combination therapy i.e. durvalumab and avelumab. Recently, the WNT/-catenin signaling 
pathway has been reported to block anti-tumour activity of tumour-infiltrating lymphocytes 
and enhance resistance to anti-PD-1/PD-L1. In addition, immune evasion was further 
promoted by STAT3 signaling; BBI608 is an inhibitor that blocks STAT3 and down-regulate 
WNT/-catenin signaling. Therefore, combination of pembrolizumab plus BBI608 is 
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currently undergoing assessment for efficacy and safety in a multicenter phase I/II trial (55).  
The trial aims to block WNT/-catenin and STAT3 signaling in 8 patients with 
MMMR competent metastatic CRC, to try to enhance the efficacy of pembrolizumab. In the 
phase I trial, patients were divided into 2 groups: for group 1, 5 patients received 240 mg BID 
everyday with 200 mg pembrolizumab; and for group 2, 3 patients received 480 mg BID 
everyday with 200 mg pembrolizumab. The result showed that one patient in group 1 
developed dose-limiting toxicity and was discontinued, however, the rest of the patients in 
this group presented no toxicity related symptoms, with no toxicity seem in group 2. 
Interestingly, one patient in group 2 demonstrated tumour shrinkage over more than 12 weeks 
with a significant decline in carcinoembryonic antigen (CEA) levels in both lung and lymph 
node metastases. From these initial results, it suggests this combination might induce anti-
tumour activity. This cohort will now continue into a phase II trial to confirm the efficacy and 
safety of this combination (56).  These results suggest that for CRC the way forward for 
immunotherapy is combination with other drugs to prime the immune landscape. Developing 
predictive biomarkers for treatment response and toxicity may further enhance this. 
 
3. Adoptive cell transfer to enhance T-cell functions 
Passive immunotherapy or cell-based therapy is based on immune effector cells that 
are generated ex vivo and then transferred into the patient known as adoptive cell transfer 
(ACT).  ACT is a type of cell-based therapy based on collecting tumour infiltrating or 
circulating lymphocytes from patients, processing them ex vivo to target a specific 
neoantigen, and then reinfusion of the cells back into patient (Figure 2). The predominant cell 
types used are T-lymphocytes and natural killer (NK) cells, which both have anti-tumour 
characteristics, cytolytic actions and produce cytokines to eliminate tumour cells (57).  
3.1 Chimeric antigen receptor T-cell therapy 
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Current ACT strategy target T-lymphocytes that are genetically modified to expressed 
chimeric antigen receptor (CAR-T), which is specific to tumour cells. They recognise native 
tumour antigen on cell surface instead of epitopes presented by human leukocyte antigen 
(HLA) molecules. Engineered CAR-T cells are linked to the intracellular signalling domain 
of T-lymphocytes by using the antibody-derived single-chain variable fragment (scFv), 
resulting in T-lymphocytes being recognised via surface antigens independent of major 
histocompatibility complex (MHC) (58). After they bind to the tumour antigen, CARs then 
activate T-lymphocytes to kill the tumour. The most important CAR-T cells are generated to 
target specific tumour cells surface antigens; this avoids unexpected autoimmune diseases. 
As CARs do not rely on HLA, they can be employed in all patients regardless of HLA 
haplotype. Currently, CAR-T cell therapy is approved to treat hematologic malignancies, 
including chronic lymphocytic leukaemia (CLL) and acute lymphocytic leukaemia (ALL) 
patients and adults with certain types of large B-cell lymphoma (59, 60). Recently, a study 
reported the potential of CAR-T cells therapy in breast cancer however more evidence is 
needed before the approval of CAR-T cell therapy for this cancer type (61). 
3.2 CAR-T cells therapy and colorectal cancer 
In CRC, CAR-T cells are being investigated for metastatic disease. Animal model for 
CAR-T cells targeting CRC antigens, classic CEA and emerging guanylyl cyclase C 
(GUCY2C), show therapeutic potential that might translate to clinical use. When targeting 
CEA, animal experiments suggest that CAR-T cells may induce tumour regression; however, 
they also cause toxicity due to cytokine release syndrome. In human trials, the initial studies 
focussed on CRC with liver metastasis, and no patients were reported to developed severe 
adverse effects; however, disease progression was not suppressed, and cancer specific 
survival was not improved.  
As for targeting GUCY2C, these have only been studies in animal models. Initial 
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results from pulmonary metastasis suggest that CAR-T cells targeting GUCY2C could reduce 
tumour burden and significantly prolong survival; however, this needs to be confirmed in 
human studies. Targeting GUCY2C showed no autoimmunity issues and had good safety and 
efficiency to treat metastatic CRC (62). From these initial results, CAR-T cells therapy has 
the potential to be a useful CRC metastasis treatment although further safety testing is 
required. 
 
4. Enhancing the efficacy of current immunotherapies 
 Although immunotherapy has shown satisfactory results in multiple types of cancer, 
many patients show no response, for example, in MMR competent CRC. Therefore, 
strategies that enhance the efficacy of immunotherapy are now the focus of many studies. 
Some approaches to enhance the efficacy of immunotherapy include performing immune 
checkpoints combination therapy to increase treatment yield, evaluating biomarkers for 
treatment responses to observe treatment effectiveness, assessing biomarkers for treatment 
toxicities to reduce treatment failure, and investigating new potential targets. 
 4.1 Immune checkpoint inhibitor combination therapy 
Currently, combinations of anti-PD-1/PD-L1 and CTLA-4 drugs are in clinical trials, 
focusing on ipilimumab with nivolumab or pembrolizumab. To date, combination trials in 
advanced melanoma have shown that a reduced dose of nivolumab combined with the 
standard dose of ipilimumab showed better response rates than ipilimumab alone, however, it 
caused more toxicity (63). Conversely, a Phase I study of standard-dose pembrolizumab 
combined with low-dose ipilimumab in advanced melanoma showed significant anti-tumour 
activity and controllable toxicity, therefore, a phase II trial is now underway (63, 64). 
4.2 Predictive biomarkers for treatment response  
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Immunotherapy may have shown disappointing results in some tumours because of 
the genetic variability or differing strengths of the host immune response within each patient. 
Therefore, specific biomarkers or clinical features that could be used to predict response to 
treatment are likely to be key improving the effectiveness of immunotherapy in these 
patients. This is already suggested with MMR status being used as a predictive marker for 
pembrolizumab and nivolumab in a variety of cancers. Another potential biomarker candidate 
for immune checkpoint therapies includes immunological biomarkers, such as intratumoral 
PD-L1. However, a study from Aguiar et al. showed that PD-L1 negative tumours still 
respond to checkpoint inhibitor drugs (65). Suggesting that intratumoural PD-L1 might not be 
an effective marker for PD-1/PD-L1 inhibitor. Recently, PD-L2 expression was also found to 
be an independent prognostic factor that may also predict the effectiveness of anti-PD-1 
therapy (66, 67).  
Biomarkers related to clinical responses to anti-PD-1, anti-PD-L1, and anti-CTLA-4 
checkpoint inhibitors therapies are currently being studied in both patient’s tumour tissue and 
blood samples (66, 68) (Table 2). In tumour tissues, many biomarkers have been studied, for 
example, tumour-infiltrating lymphocytes (TILs), PD-L1 expression, and mutational load. 
TILs present in the intratumoral site have been shown to be associated with improved clinical 
benefit for anti-CTLA-4 therapy in advanced melanoma (69). Also, PD-L1 expression has 
been shown to associate with improved clinical benefit from anti-PD-1/anti-PD-L1 therapy in 
multiple cancer types including advanced melanoma and breast cancer (70, 71). Furthermore, 
mutational load has been performed in both anti-CTLA-4 and anti-PD-1 therapy. In 
melanoma, it was shown that high mutational load related to improved efficacy for anti-
CTLA4 therapy (72); whereas in NSCLC high mutational load was associated with better 
efficacy for anti-PD-1 therapy (73). From these studies, it suggests that assessing treatment 
responses using various predictive biomarkers may benefit immunotherapy outcomes. 
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In blood samples, several biomarkers have been studied including circulating 
leukocytes (lymphocytes, neutrophils, eosinophils, and monocytes), myeloid-derived 
suppressor cells (MDSCs) level, and lactate dehydrogenase (LDH) level. For anti-CTLA-4, 
high lymphocytes level during treatment related to better overall survival on this therapy 
(74). Furthermore, the neutrophil-to-lymphocyte ratio (NLR) declined during on-going 
treatment and this showed association with a higher survival rate (75). In contrast, high serum 
LDH level prior to treatment with anti-CTLA-4 therapy was associated with resistance to 
treatment (76). Although wide varieties of biomarkers have been investigated in multiple 
cancers, validation is now required before translation into clinical setting can be achieved.   
4.3 Predictive biomarkers for toxicity 
One issue with checkpoint inhibitors is that the treatment can cause severe immune-
related adverse events (irAEs), frequently affecting the skin, intestinal tract, liver, and 
endocrine system. These irAEs occur more frequently with anti-CTLA-4 antibody than anti-
PD-1/anti-PD-L1 antibody [61]. As these can be life threatening they often lead to therapy 
being stopped. Therefore, predictive biomarkers that test for toxicity in patients are also 
needed to improve both the patient’s quality of life and survival outcomes.  
Biomarkers associated with ipilimumab treatment toxicities in melanoma patients 
have been studied in colon tissue to investigate toxicity within the intestinal tract (77). The 
result showed that neutrophil infiltration within the lamina propria of colon biopsies and 
other markers of digestive dysregulation including histological observation, faecal 
calprotectin, and antibodies for enteric flora were associated with digestive toxicity. This 
suggests that ipilimumab induces colitis as confirmed by Marthey et al. (78), who then 
investigated these biomarkers during drug administration and showed they could be of 
benefit for predicting these adverse effects and improving the quality of life of the patients.  
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Similarly, another study using blood samples of melanoma patients treated with 
ipilimumab measured eosinophils level before and after treatment. The result showed that 
absolute eosinophil counts increased over treatment and were associated with the occurrence 
of irAEs (79). To address this further, gene expression profiles of peripheral bloods from 
advanced melanoma patients treated with ipilimumab, that had developed gastrointestinal 
tract irAEs, were investigated (80). The result showed increase expression of neutrophil 
markers, CD177 and carcinoembryonic antigen-related cell adhesion molecule 1 
(CEACAM1), during treatment supporting the potential role of neutrophil in irAEs of 
ipilimumab within the gastrointestinal tract. However, further studies from larger cohorts of 
patients are needed as well as other more specific predictive markers in order for early 
management of irAEs to occur.  
4.4 Alternative targets for immunotherapy 
At present, apart from targeting PD-1/PD-L1 and CTLA4 pathway, many other 
immune pathways are being targeted including macrophage targeting therapy, cytokine 
therapy, toll-like receptor (TLR) agonists, and other checkpoint inhibitors including T-cell 
membrane protein (TIM-3 or HAVcr2), lymphocyte activation gene (LAG-3 or CD223), B- 
and T-lymphocyte attenuator (BTLA or CD272), and V-domain Ig suppressor of T-cell 
activation (VISTA) (64). As a result, personalized medicine using these targeted 
immunotherapies is the main focus for future cancer treatments combined with actively 
seeking predictive biomarkers to increase responsiveness to these treatments. 
Novel approaches to immunotherapy are also under investigation including utilizing a 
new-targeted drug delivery system for CD8+ T-lymphocytes called nanoparticles that was 
proposed by Schmid et al. (81). The study in mice utilized antibody-targeted nanoparticles 
bound to CD8+ T-lymphocytes in blood, lymphoid tissues, and the tumour. The result showed 
the nanoparticles successfully targeted PD-1+ T-lymphocytes in the blood and tumour. Using 
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these nanoparticles, a TGF inhibitor was delivered to PD-1 expressing cells and showed 
extra survival benefit compared to delivering the inhibitor as a free drug at the same dose. 
Nanoparticles also modulated the ratio of tumour infiltrating CD8+ T-lymphocytes and 
sensitized tumours to anti-PD-1 therapy (81). From the results, using nanoparticles targeting 
specific effector cell’s function to kill tumour cells and inhibit suppressor cells at the same 
time could potentially change non-responder to responder for immunotherapy.  
Other delivery methods are also under development including peptides and antibody-
based systems. Furthermore, cellular mechanisms, such as cellular influx, are being 
investigated to deliver immune regulating compounds to the tumour area (82). Overall, it is 
promising time for the use of immunotherapy as a treatment for solid and hematological 
tumours.  Furthermore, enhancing the efficacy of these treatments via combination therapies 
and utilizing biomarkers could expand the treatments prospects.  
 
5. Conclusions 
In conclusion, the immune system plays an essential role in cancer progression 
through mechanisms regulated by multiple immune cells types in tumour microenvironment. 
Of these, immune checkpoints, such as PD-1/PD-L1 and CTLA-4, are crucial proteins that 
inhibit the immune system anti-tumour effects and promote tumour progression. Therefore, 
immunotherapy targeting immune checkpoints to restore the killing function of immune cells 
is an alternative treatment strategy. Currently, there are many drugs targeting PD-1/PD-L1 
and CTLA-4 that are approved to treat multiple tumour types, with nivolumab and 
pembrolizumab at the forefront of many clinical trials.  
However, not all patients respond to these treatments and this might be due to 
differences at a genomic or immune level within each patient that is affecting their response 
to the drug’s action. Therefore, biomarkers that predict response to treatment are also 
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essential for immunotherapies success.  As a result, combination therapies of immunotherapy 
and conventional chemotherapy or radiotherapy are being investigated to see if these can 
prime the immune system to enhance the efficacy of the immunotherapy. Furthermore, 
targeting of other checkpoint inhibitors and immune pathways are being investigated to 
enhance the effectiveness of immunotherapy and move towards a more personalized therapy 
approach. Additionally, utilizing nanoparticles as a new-targeted drug delivery system to 
target CD8+ T-lymphocytes to the tumour is a novel approach to immunotherapy that may 
enhance adoptive CAR-T cells therapy and is currently a major focus of many clinical trials. 
Overall, immunotherapy could be a powerful tool to fight multiple cancers; nevertheless, 
more investigation is needed to enhance efficacy and reduce toxicity within patients.  
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Figure legends: 
 
Figure 1. Immune checkpoint interactions that inhibit T-cells function and their 
inhibitors. Immune checkpoint, PD-1 on activated T-cell binds to specific receptors, PD-L1 
and PD-L2, on tumour cells, whereas CTLA-4 on resting T-cell binds to B7 on antigen-
presenting cells, both to inhibit T-cells function. Immune checkpoint inhibitors, anti PD-1, 
anti-PD-L1, and anti CTLA-4 can block these complexes to restore T-cells function. 
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Figure 2. General principle of CAR-T cell therapy T-lymphocytes from patient’s blood are 
engineered in vitro to express chimeric antigen receptor (CAR) to enhance T-cells binding to 
tumour antigens, after expansion with IL2 they are re-infused into patient to bind to tumour 
receptors and enhance killing of tumour cells.  
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Table 1. Summary of immune checkpoint inhibitors approved for multiple cancers.  
 
Antibody Drug name Year Approved for Reference studies Phase Response rate References 
Anti PD-1 Pembrolizumab 2014 Advanced melanoma KEYNOTE-006 (NCT01866319) Phase III 33.7% (18) 
  
2015 Advanced non-small-cell lung cancer (NSCLC) KEYNOTE-001 (NCT01295827) Phase I 19.4% (19) 
  
2016 
Recurrent or metastatic head and neck squamous cell 
carcinoma (HNSCC) 
KEYNOTE-012 (NCT01848834) Phase II 16.0% (20) 
  
2017 Classical Hodgkin lymphoma (cHL) KEYNOTE-087 (NCT02453594) Phase II 69.0% (22) 
  
2017 Metastatic urothelial carcinoma (mUCC) KEYNOTE-052 (NCT02335424) Phase II 38.0% (23) 
  
2017 Non-resectable or metastatic MSI-H/dMMR KEYNOTE-016 (NCT01876511) Phase II 
 
(24) 
    KEYNOTE-164 (NCT02460198) Phase II  (25) 
    KEYNOTE-012 (NCT01848834) Phase II 39.6% (Pooled) (20) 
    KEYNOTE-028 (NCT02054806) Phase Ib  (26) 
    KEYNOTE-158 (NCT02628067) Phase II  (27) 
  
2017 Gastroesophageal junction (GEJ) carcinoma  KEYNOTE-059 (NCT02335411) Phase II 13.3% (MSI-H 57%) (28) 
  
2018 Recurrent or metastatic cervical cancer (RCC) KEYNOTE-158 (NCT02628067) Phase II 13.3% (29) 
  
2018 Large B-cell lymphoma (PMBCL) KEYNOTE-170 (NCT02576990) Phase II 45.0% (30) 
 
Nivolumab 2014 Metastatic melanoma CHECKMATE-037 (NCT01721746) Phase III 32.0% (31) 
    CHECKMATE-066 (NCT01721772) Phase III 40.0%, (32) 
  
2015 Metastatic non-small-cell lung cancer (NSCLC) CHECKMATE-057 (NCT01673867) Phase III 19.2% (33) 
  
2015 Advanced metastatic renal cell carcinoma (RCC) CHECKMATE-025 (NCT01668784) Phase III 25.0% (34) 
  
2016 
Recurrent or metastatic head and neck squamous cell 
carcinoma (HNSCC) 
CHECKMATE-141 (NCT02105636) Phase III 13.3% (35) 
 
Cemiplimab 2018 Metastatic cutaneous squamous cell carcinoma (CSCC) NCT02383212 Phase I 52.0% (36) 
Anti PD-L1 Atezolizumab 2016 Advanced urothelial carcinoma IMVigor210 (NCT02108652) Phase II 23.5% (38) 
  
2016 Metastatic non-small cell lung cancer (NSCLC) OAK (NCT02008227) Phase III 14% (39) 
    POPLAR (NCT01903993) Phase II 14.3 months (40) 
 
Avelumab 2017 Merkel cell cancer NCT02155647 Phase II 31.0% (41) 
  
2017 Urothelial carcinoma NCT01772004 Phase Ib 16.5% (42) 
 
Durvalumab 2017 Metastatic urothelial carcinoma (mUCC) NCT02516241 Phase III 17.8% (43) 
  
2018 Metastatic non-small cell lung cancer (NSCLC) NCT02125461 Random 28.4% (44) 
Anti CTLA-4 Ipilimumab 2014 Metastatic melanoma NCT00094653 Phase III 10.9% (46) 
  
2018 Renal cell carcinoma CHECKMATE-214 (NCT02231749) Phase III 42% (47) 
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Table 2. Potential biomarkers associated with immune checkpoint inhibitors treatment 
response and toxicity. 
 
Samples Biomarkers Antibody References 
Potential biomarkers associated with treatment response  
  
     Tumour tissues Tumour infiltrating lymphocytes (TILs) Anti CTLA-4 (60) 
 
PD-L1 expression Anti PD-1 (61,62) 
 
Mutational load Anti CTLA-4  (6) 
  Anti PD-1 (64) 
     Blood  Circulating leukocytes Anti CTLA-4 (65) 
 
Neutrophil-to-lymphocyte ratio (NLR) Anti CTLA-4 (66) 
 
Lactate dehydrogenase (LDH) level Anti CTLA-4 (67) 
Potential biomarkers associated with treatment toxicity 
  
     Tumour tissues Neutrophil infiltration Anti CTLA-4 (68,69) 
     Blood  Eosinophil level  Anti CTLA-4 (70) 
 
 
 
 
 
 
 
 
